Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- sneezing
- nasal pruritus
Otros factores de diagnóstico
- palate, throat, ear, and eye itching
- eye redness, puffiness, and watery discharge
- fatigue and irritability
- nasal congestion
- rhinorrhea
- allergic shiners
- conjunctival injection
- ocular mucoid discharge
- nasal crease
- pale nasal mucosa
- swelling of the nasal mucosa and turbinates
- abundant clear nasal secretions
- Dennie-Morgan lines (creases present under the lower eyelids)
Factores de riesgo
- other atopic conditions or family history of atopy
- age <20 years
- exposure to aeroallergens (pollen, molds, house dust mites, pollution)
- exposure to animal dander
- ethnicity
- positive allergen skin-prick tests
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- therapeutic trial of antihistamine or intranasal corticosteroid
Tests to avoid
- immunoglobulin G (lgG) testing
- sinonasal imaging
Pruebas diagnósticas que deben considerarse
- allergen skin-prick testing
- in vitro specific IgE determination
Algoritmo de tratamiento
mild or intermittent symptoms
persistent and moderate to severe symptoms
usual therapy ineffective or poorly tolerated
Colaboradores
Autores
Gary C. Steven, MD, PhD, CPI, FAAAAI, FACAAI, FAPCR
Medical Director
American Academy of Allergy, Asthma & Immunology Registry
Assistant Clinical Professor of Medicine
Medical College of Wisconsin
Adjunct Clinical Instructor
College of Nursing
University of Wisconsin-Milwaukee
Allergy, Asthma & Sinus Center
Milwaukee
WI
Divulgaciones
GCS has taken part in sponsored research for the ALK clinical trial of the house dust mite SLIT tablet for use in pediatric patients. He is a member of the Joint Task Force on Practice Parameters Workgroup on the Allergic Rhinitis Practice Parameter.
Agradecimientos
Dr Gary C. Steven would like to gratefully acknowledge Dr Alexander Greiner, a previous contributor to this topic.
Divulgaciones
AG has received grant/research support from: AstraZeneca; Boehringer Ingelheim; Cephalon Circassia Ltd; Clement Clarke Cytos biotechnology; GlaxoSmithKline; Glenmark Specialty, S.A.; Hoffman-LaRoche/Genentech; HRA/Novartis; Janssen Research & Development; Kalypsys , Inc.; Lupin; Merck; Mylan Pharmaceuticals, Inc.; Nestle (Nestec Ltd); Novartis Ono Pharmaceutical Co., Ltd.; Perrigo; Rigel Pharmaceuticals, Inc.; Roxane Laboratories Inc.; Shionogi Inc.; Sunovion TEVA Branded Pharmaceutical Products; UBC (United Biosource Corporation)/Amgen Pharmaceuticals; and sponsorship for pharmaceutical trials from Allergen Research Corporation/Aimmune Therapeutics, Inc. and AstraZeneca.
Revisores por pares
Mark Davis-Lorton, MD
Clinical Immunology Coordinator
Division of Rheumatology, Immunology and Allergy
Winthrop-University Hospital
Mineola
NY
Divulgaciones
MDL declares that he has no competing interests.
Glenis Scadding, MD
Consultant Allergist/Rhinologist
Allergy & Rhinology Department
Royal National Throat, Nose and Ear Hospital
London
UK
Divulgaciones
GS is a consultant/advisory board member for ALK, Britannia Pharmaceuticals, CMP Therapeutics, Grupo Uriach, GSK, Merck, Sanofi-Aventis, Schering Plough, and UCB. She has received research funds from ALK, GSK, UCB, and Schering Plough. She has given talks for ALK, GSK, Merck, Schering Plough, and UCB and has co-written articles for Schering Plough and GSK.
Diferenciales
- Nonallergic rhinitis
- Acute sinusitis
- Chronic sinusitis
Más DiferencialesGuías de práctica clínica
- Clinical practice guideline: immunotherapy for inhalant allergy
- Australasian guidelines for allergic rhinitis 2022
Más Guías de práctica clínicaFolletos para el paciente
Hay fever
Hay fever: avoiding pollen and mold
Más Folletos para el paciente
Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad